Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Thursday

Processa Pharmaceuticals (NASDAQ:PCSA) is projected to release its earnings data on Thursday, March 27th. Analysts expect Processa Pharmaceuticals to post earnings of ($0.76) per share for the quarter.

Processa Pharmaceuticals Stock Performance

NASDAQ PCSA opened at $0.42 on Thursday. The company’s 50-day simple moving average is $0.61 and its two-hundred day simple moving average is $0.97. Processa Pharmaceuticals has a one year low of $0.40 and a one year high of $3.31. The company has a market capitalization of $1.39 million, a price-to-earnings ratio of -0.13 and a beta of 0.75.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Processa Pharmaceuticals in a research note on Thursday, December 5th.

Insider Buying and Selling

In other Processa Pharmaceuticals news, CEO George K. Ng acquired 87,200 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were acquired at an average cost of $0.80 per share, with a total value of $69,760.00. Following the acquisition, the chief executive officer now directly owns 87,200 shares of the company’s stock, valued at approximately $69,760. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David Young acquired 124,500 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $99,600.00. Following the completion of the acquisition, the insider now directly owns 205,405 shares in the company, valued at approximately $164,324. The trade was a 153.88 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 224,100 shares of company stock worth $179,280 in the last 90 days. 13.00% of the stock is owned by corporate insiders.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.